Xencor, Inc. (XNCR) Discusses Initial Phase I Dose Escalation Results for XmAb819 in Advanced Clear Cell Renal Cell Carcinoma Transcript

Core Points - The webcast is focused on the initial Phase I dose escalation results for Xencor's XmAb819 [1] Group 1 - The conference is hosted by Megan, the conference operator, who introduces the event [1] - Charles Liles, Senior Director of Corporate Communications and Investor Relations, is set to take over the call [1]